Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oral Boards > Lymphoma > Flashcards

Lymphoma Flashcards

1
Q

Lymphoma: GHSG unfavorable factors

A

≥3 nodal sites

bulky ≥1/3 chest

extranodal involvement

ESR ≥30 with B and ≥50 without B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Lymphoma: NCCN unfavorable factors

A

≥4 nodal sites

bulky disease >10 cm or mediastinal mass ratio >1/3

ANY B symptoms

Not counted: extranodal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Lymphoma: sim for head/neck, chest, abdomen, pelvis

A

H&N: do dental eval first. Use bite block to divert tongue away from field if possible. Mask.

Chest: 4DCT, vac loc. Breath hold increasing in use to spare heart and lung

Abdomen: 4DCT. Empty stomach and treat at same time each day. If using oral contrast also sim without contrast. Daily CBCT.

Pelvis: If young age, do pregnancy testing and fertility testing. Consider sperm banking, egg banking, ovarian transposition, testicular clamshell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ABVD: components and dose

A

Doxorubicin 25 mg/m2, d1 and 15

Bleomycin 10 U/m2, d1 and 15

Vinblastine 6 mg/m2, d1 and 15

Dacarbazine375 mg/m2, d1 and 15

Q4w

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

R-CHOP: components and dose

A

Rituximab 375 mg/m2, d1

Cyclophophamide 750 mg/m2, d1

Doxorubicin 50 mg/m2, d1

Vincristine 1.4 mg/m2 (max 2 mg), d1

Prednisone 100 mg po qd d1-5

Q3w x 6-8 cycles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

BEACOPP: components

A

Bleomycin

Etoposide

Doxorubicin

Cyclophosphamide

Vincristine

Procarbazine

Prednisone

Q3w

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Lugano staging tips for HL and DLBCL

A
  • PET is adequate to assess bone marrow involvement and can be highly suggestive for extralymphatic involvement
  • Routine bone marrow biopsy no longer indicated for HL and DLBCL.
  • Consider bone marrow biopsy in HL if cytopopenias present and consider in DLBCL if suspecting a different histology
  • BM biopsy still required in follicular, MZL, burkitt’s
  • Use A and B status only for Hodgkin, not NHL
  • For bulky, add the word “bulky” to the stage, not letter X
  • Bulky disease in HL is >10 cm or >1/3 the transthoracic diameter. CT is appropriate (CXR not required)
  • For extranodal, use letter E modifier. Extranodal is only applicable for Stage I-II per Lugano. No such thing as Stage IIIE or IVE. Just Stage III and IV.
  • Splenomegaly is defined as size >13 cm. PET avidity is not relevant when determining splenomegaly
  • Hepatomegaly is focal or disseminated PET avidity
  • Bulky in NHL is definted as ≥7.5 cm per NCCN and DSHNHL RICOVER (not defined in Lugano)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Lymphoma: follow up

A

Year 1-2 q 3 mo, Year 3-5 q 6mo: H&P, CBC/plt/ESR

imaging at 6, 12, and 24 mos

Annual flu shot, TSH, CXR, counseling on fertility, psychosocial, reproduction, cardiovascular, breast self exam, skin cancer risk

After 5 years - annual BP check, echo/stress test/carotid US screening q10 yrs, mammogram at 8 yr or age 40 (MRI if age 10-30 at treatment), CBC/chem/TSH/lipids, CXR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lymphoma nodal sites

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HL: workup

A

H&P, B symptoms of fever, weight loss >10%, drenching nightsweats, performane status, ETOH induced pain/pruritis, complete LN exam, Waldeyer’s ring, palpation of abd/spleen/liver

Excisional biopsy of node. IHC. May require FISH and cytogenetics

Labs: CBC w/ diff, LFTs, CMP, ESR, LDH, beta-HCG, HIV test, Hepatitis B

Studies: CXR, CT C/A/P, PET. Now only do BM bx if PET negative and cytopenias present (Lugano)

(Note that LN regions are different per system used- many focus on GHSG regions since tx guided by these trials.)

Pre chemo assessment: Echo/MUGA, PFTs

Extra workup: dental eval if treating neck, fertility sparing: Gyn consult, oophoropexy, or sperm banking

If excisional bx not feasible, can do core needle bx with immunohistochem, flow cytometry, FISH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Early stage favorable HL: treatment paradigm

A

ABVD x 2 cycles then obtain post-chemo PET.

Deauville ≤3 give 20 Gy/ 10 fx

Deauville 4 give two more cycles and reassess

Deauville 5, biopsy first, and if positive see refractory pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Early stage favorable HL: 10yr OS and PFS on HD10

A

10yr OS 94%

10yr PFS 87%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Early stage unfavorable HL: treatment paradigm

A

chemo, then post-chemo PET. If Deauville 1-3, treat with RT. If Deauville 4, consider another 2 cycles of chemo

Varous regimens:

30Gy/15fxs after ABVD x4 per HD11

20Gy/10fxs after escBEACOPP x 4 per HD11

30Gy/15fxs after escBEACOPPx2 + ABVDx2 per HD14 (best results)

36Gy/18fxs for bulky

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Early stage unfavorable HL: 5yr OS and PFS on HD11

A

5yr OS 94%

5yr PFS 87%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

stage III/IV HL: indications for radiation

A

partial response, bulky disease, or bone involvement

typically 30Gy/15fxs, maybe higher if bone involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

stage III/IV HL: poor prognostic factors

A

MASHAWL

male

age>45

stage IV

Hgb<10.5

albumin<4

WBC>15

lymphocyte<0.6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DLBCL: workup

A

Same workup as Hodgkins, except:

Don’t need ESR. Add uric acid.

Obtain Hepatitis B labs (for rituximab)

Karyotype or FISH for double hit (bcl2, bcl6, myc)

Bone marrow is also optional in DLBCL (Lugano criteria). Consider if PET is negative but may be looking for other subtype in marrow (still need bone marrow for follicular, MZL, and burkitt)

LP in DLBCL for testicular, paranasal sinus, epidural, or HIV assoc lymphoma, or if more than 2 extranodal sites and elevated LDH (NCCN)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

IPI score

A

age>60

PS>1

LDH>1.5x nl

extranodal dx in more than one site

stage III/IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IPI score: 5yr OS by score (rituximab era)

A

5yr OS:

score 0: 95%

score 1-2: 80%

score 3-5: 55%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Early stage DLBCL: radiation doses

A

36Gy for bulky tumor or bony disease

40Gy for partial response on PET

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Early stage DLBCL: treatment paradigm

A

R-CHOP x 3-6 cycles. Some give 6 if IPI score ≥2 or bulky.

3 cycles with RT if Deaville 1-3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

characteristics of primary mediastinal B-cell lymphoma

A

An NHL. Distinct from DLBCL by CD markers, often CD20+. CD15- and CD30 weakly + or -. BCL6 positive.

Path: fibrosis, necrosis, and thymic cells. No nodularity (nodularity is seen in classical HL and NLPHL). Sheets or irregular clusters of large cells, may resemble R-S cells.

Arises in thymus (extranodal), common in women, usually stage I-II. Arises in anterior MS, sometimes also with cervical and SCV nodes. More common in females 2:1, usually age 30s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

primary mediastinal B-cell lymphoma: treatment paradigm and outcome

A

(DA) R-EPOCH x6 is often used (NIH), then assess response with PET.

Consider RT 30-36 Gy for Deauville 4-5

Consider RT to 36 Gy for bulky

5yr OS 95%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

(DA) R-EPOCH: components

A

Dose Adjusted based on ANC and platelet counts

rituximab

etoposide

prednisone

vincristine

cyclophosphamide

doxorubicin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

lymphocyte predominant HL: characteristics

A

A HL. Markers similar to PMBCL except CD30. CD20+, CD15-, CD30-(very rarely CD30+).

Path: popcorn cells (large cells with multilobulated or round nuclei) and nodularity and replacement of nodal architecture.

80% present as early stage. Usually peripheral adenopathy with central sparing. Often extranodal. Some will relapse but relapse survival still better than HL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

lymphocyte predominant HL: treatment paradigm for IA/IIA nonbulky

A

30 Gy if <5 cm, 36 Gy if >5 cm

treatment is RABVD or RCHOP +/- xrt for IB/IIB or bulky disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

cutaneous B-cell lymphoma: workup

A

(marginal zone or follicular)

Standard H&P with attention to full skin exam.

Biopsy (punch, excisional, or incisional).

For T cell get peripheral smear for Sezary cells (necessary for staging)

CT C/A/P and/or PET. BM Bx useful for select cases

5-10% present with sezary syndrome: >1000 cells/uL usually with generalized erythroderma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

total skin electron beam therapy: narrative

A

I would position the patient at 3 m SSD with beam spoiler 1 cm thick placed in front of the patient. I would treat 3, out of total 6, positions per day for 4 days per week, delivering 1 Gy per day, ensuring to boost areas of possible underdosage including soles, perineum, scalp, under breasts and pannus. I would place TLDs to confirm adequate dosage. The beam would be moved + and – 20 degrees.”;;Treat in 6 positions to cover total skin, 3 positions per day, 4 days per week. Boost to soles, perineum, and scalp. Also need to boost “shadow areas” under breast, pannus, etc. Can shield eyes. Can intermittently shield nail beds and tops of feet to reduce risk of edema. Put TLDs on areas at risk of underdosage such as scalp vertex, axilla, inframmary folds, perineum, intergluteal cleft, medial thighs, soles of feet, palms (patient usually is supported by handles).;;A beam spoiler 1 cm thick is placed in front of patient to increase large angle scatter and improve dose homogeneity. The beam is positioned 3 m SSD and moved +/- 20 degrees (angles reduce photon contamination to less than 1%). Goal is to achieve dose homogeneity in the coronal plane. Rx and Dmax are at skin surface, and 80% dose is at 0.7-1.0 cm depth

29
Q

cutaneous B-cell lymphoma: doses

A

Generally only local RT for B cell; never total skin.

1.0-1.5 cm margin

Low grade: 24-40 Gy

Int grade: RCHOP x3 + RT up to 36 Gy

Palliative: 2x2 Gy gives CR in 70%

30
Q

cutaneous T-cell lymphoma: doses

A

Localized: electrons to 20-24 Gy with at least 2 cm margin. Some treat up to 36 Gy.

Generalized: TSEBT to 10-12 Gy (1 Gy per day, 4 days per week, for 3 weeks) per guidelines. With this regimen retreatment is allowed

Palliation: 2x2 Gy repeated until good response or single dose 8 Gy. Margin 1-2 cm

(ILROG guidelines)

31
Q

cutaneous B-cell lymphoma: treatment options aside from xrt

A

intralesional steroids, R,topicals, other systemic therapy such as is used for follicular lymphoma

32
Q

cutaneous T-cell lymphoma: treatment options aside from xrt

A

Localized options: topical corticosteroids, nitrogen mustard, imiquinod, retinoids, phototherapy

Systemic options (localized or diffuse): retinoids, interferon, HDAC inhibitors (vorinistat), electrocorporeal photophoresis, methotrexate

33
Q

total skin electron beam therapy: side effects

A

desquamation, hair loss, lymphedema, nail loss, loss of sweating, second malignancy

34
Q

gastric MALT: workup

A

H&P per lymphoma.

Imaging: CT C/A/P. Upper endoscopy, EUS and biopsy.

FISH for t(11;18). Look for H pylori on path (use modified Geimsa stain). If negative, get blood Ab test, urea breath test, or stool Ab test.

Labs: CBC, LDH, CMP. Consider BHCG

Staging imaging: CT C/A/P and PET (PET is now rec on NCCN, but caution: often not FDG avid)

35
Q

H. pylori+ gastric MALT: antibiotic regimens

A

1st line triple therapy: PPI, clarithromycin, amoxicillin. (“CAP”)

2nd line quadruple therapy: PPI, bismuth, metronidazole, tetracycline. (“P BMT”);

36
Q

gastric MALT: indications for xrt

A

H. pylori positive after failure with antibiotics

H. pylori negative

t(11;18) positive more likely to fail antibiotics but still try

37
Q

gastric MALT: follow up after antibiotics

A

Endoscopy with bx in 3 mos. General guide: if still H pylori+ give 2nd line abx, if lymph+ give RT:

pylori/lymph- —> no further therapy

H pylori+/lymph- —> 2nd line abx (PBMT)

H pylori-/lymph+ —> RT

lymph+/H pylori+ —> 2nd line abx PBMT if stable. If symptoms or progessive dz give RT + 2nd ABX PBMT

38
Q

gastric MALT: sim

A

supine, wingboard, 4DCT, optional 10 cc oral contrast, empty stomach (treat in AM or NPO for 3 hours).

39
Q

gastric malt: dose and fields

A

30Gy/20fxs

CTV: EGD to duodenal bulb, also including any positive nodes

ITV: add another 1-2 cm per extranodal guidelines

PTV: add another 1 cm

Might be able to reduce margins with daily CBCT

IMRT or 4-field

40
Q

gastric MALT: outcomes

A

MALT 5-yr OS 95%

90% MALT are H pylori +

41
Q

NK T-cell lymphoma: workup

A

Include evaluation of nasopharynx with flexible scope, testicular exam, skin exam, CSF analysis, EBV viral load, MRI nasopharynx

42
Q

NK T-cell lymphoma: treatment paradigm

A

stage I: radiation alone (50Gy + boost)

stage II-IV: chemoradiation

VIPD then 45Gy

40Gy with concurrent cisplatin then VIPD x3 cycles (Korea)

43
Q

VIPD: components

A

etoposide, ifosfamide, cisplatin, dexamethasone

44
Q

SMILE: components

A

steroid dex, MTX, ifosphamide, pegaspargase, etoposide

45
Q

NK T-cell lymphoma: xrt fields

A

Always include bilateral nasal cavity, bilateral anterior ethmoid, hard palate and ipsilateral maxillary sinus. Bilateral maxillary sinus tumor of bilateral or posterior nasal cavity.

Include adjacent structures or nodes only if these are involved

No elective neck radiation, even if nodes involved.

Use ISRT.

Waldeyers ring location: cover entire ring.

46
Q

NK T-cell lymphoma: outcomes

A

3yr OS 85%

3yr LC 60%

47
Q

follicular lymphoma: workup

A

In follicular lymphoma, excisional biopsy still recommended as in all lymphomas. If excisional bx not feasible, can do core needle bx with immunohistochem, flow cytometry, FISH.

FISH testing: if 1p36 translocation positive, disease will be localized and no staging studies are needed

Labs: Hep B, B2 microglobin plus standard

BM bx (still required in follicular with Lugano)

48
Q

follicular lymphoma: treatment paradigm

A

stage I-II, grade 1-2: xrt alone (24Gy)

stage I-II, grade 3: treated like DLBCL (R-CHOP + xrt)

49
Q

FLIPI score components

A

LNASH

LDH elevated

Nodal areas > 4

Age > 60

stage III-IV

Hgb < 12

50
Q

FLIPI 5yr OS by score

A

5yr OS:

0-1 points 90%

2 points 80%

3-5 points 50%

51
Q

FLIPI-2 score components

A

BBLAH

B2 microglobin elevated

bone marrow positive

ymph node > 6cm

age > 60

Hgb < 12

52
Q

Testicular DLBCL: workup

A

Standard workup and PET plus:

LP and CSF

MRI brain

skin exam

(bilateral involvement is still stage I)

53
Q

Testicular DLBCL: treatment paradigm

A

orchiectomy -> 6 cycles RCHOP + 4 cycles intrathecal MTX -> RT to contralateral testicle, scrotum

25-30 Gy in 1.5-2 Gy per fx, use electrons. Include nodes only if involved

54
Q

Testicular DLBCL: 5yr OS

A

5yr OS 85%

55
Q

Ocular lymphoma: workup

A

For MALT: upper and lower endoscopy

CT C/A/P

Consider PET

56
Q

Orbital DLBCL: treatment paradigm

A

30 Gy for CR if after chemo.

For residual disease consider 40-45 Gy.

Include entire orbit. May boost to gross disease

57
Q

intraocular DLBCL: treatment paradigm

A

vitreous biosy

36Gy to globe and optic nerve extending to chiasm

58
Q

MZL/MALT: general approach

A

PET. BM bx is required per Lugano.

An Indolent lymphoma per ILROG extranodal guidelines

RT alone to 24 Gy (20-30 Gy)

Per NCCN surgery alone is allowed for parotid, breast, lung, thyroid

59
Q

mantle cell lymphoma: workup

A

Standard workup

Examine H&N area including waldeyer ring, size of liver and spleen

EGD to look for MALT is optional

PET

BM bx in all

Extremely rare to see localized disease

60
Q

mantle cell lymphoma: treatment paradigm for stage I-III

A

induction hyper-CVAD

30Gy ISRT

61
Q

solitary plasmacytoma: workup

A

CT and MRI of affected area. Consider MRI spine

H&P, CBC, CMP (Calcium, albumin), LDH, beta-2 microglobulin, SPEP, UPEP, serum and urine immunofixation, skeletal survey, bone marrow bx with IHC + flow, cytogenetics, FISH analysis, serum free light chain, 24 hr urine protein

For multiple myeloma need all of:

  • BM plasma cells >10% OR plasmacytoma
  • serum or urine monoclonal protein
  • CRAB: one of calcium, renal insufficiency, anemia, osteolytic bone lesions

Multiple skeletal lesions also diagnoses MM

62
Q

solitary plasmacytoma: dose and field

A

40-50Gy

Osseous: involved lesion plus margin

Extraosseous: involved lesion, and consider adding regional lymph nodes

Conservative: Give 2-3 cm to block edge. If vertebral body, treat that entire vertebra, 1 level only

Other strategy: Treat whole bone. Treat one vertebral body above and below

63
Q

solitary plasmacytoma: likelihood of transformation to multiple myeloma

A

osseous: 60%
extraosseous: 40%

64
Q

TBI narrative

A

I would position the patient at 4 m SSD standing, treating AP/PA. I would have measured the patient to create compensators and I would place a beam spoiler in front of the patient for appropriate dose distribution. Lead would be used to protect the lungs. (ablative) I would deliver 1.5 Gy BID for four days total to total 12 Gy, 5-10 cGy/min for ablation, with fludarabine and cyclophosphamide chemotherapy and nausea prophylaxis. I would keep the lung dose <10 Gy.

65
Q

TBI treatment fields

A

Treat AP/PA

  • Treat at 400 cm SSD
  • I would first measure the patient to create compensators for appropriate dose distribution. I would give zofran for nausea prophylaxis
  • Patient standing
  • Treat at extended SSD with beam spoiler
  • Treat with 12 Gy, BID dosing, 5-10 cGy/min, lung dose <10 Gy for ablative with fludarabine/cyclophosphamide
66
Q

relapsed/refractory HL: criteria for transplant

A

General indications:

Localized relapse

Bulky disease

Persistent FDG uptake after ICE or ASCT

Critical for LC (nerve compression, SVC compression, airway compression, lymphedema, hydronephrosis)

Desseminated disease may be all treated with RT of toxicity profile is reasonable

67
Q

relapsed/refractory HL: treatment paradigm

A

(ILROG guidelines)

ISRT is appropriate with autologous SCT and can be given before or after SCT.

CR after salvage chemo (often ICE):

CR Deauville 1-3: consider 30 Gy, or 36 Gy for Deauvile 3

CR on PET (D score 1-3) but >2.5 cm on CT: 36 Gy

Previously irradiated: ≥18 Gy as dosimetry allows

Prior to ASCT or 4-12 weeks after

PR (Deauville 4) after salvage chemo:

PR sites to 36-40 Gy and CR sites to 30-36 Gy

May treat only PR sites if volume is large

TLI: 18 Gy in 1.8 Gy BID over 1-2 weeks to refractory disease followed by 18 Gy in same fx to TLI

Give RT prior to ASCT with goal of minimal residual disease

May also consider further chemo

Deauville 5 after salvage chemo:

If limited refractory, consider RT as above

RT not rec for disseminated disease

RT before ASCT is favored

consider 40-45 Gy

68
Q

relapsed/refractory DLBCL: treatment paradigm

A

(ILROG guidelines)

CR (Deauville 1-3) to salvage chemo:

30-36 Gy / 1.5-2.0 Gy per fx pre- or post-transplant

30 Gy / 1.5 Gy BID is an option for urgency pre-transplant

Post-transplant is done within 4-12 wks after

Pre-transplant is done ASAP, within 4 weeks after chemo

Volume: ISRT. Can consider including adjacent nodes that responded to first line chemo

PR (Deauville 4-5) residual focus after salvage chemo:

36 Gy / 1.8-2 Gy per fx with boost to 40-45 Gy / 1.8-2.2 Gy per fx to PR site

Volume and timing as above

69
Q

Deauville scoring

A
  1. No uptake
  2. Uptake ≤mediastinum
  3. Uptake >mediastinum but ≤liver
  4. Uptake moderately >liver
  5. Uptake markedly >>liver

Score of 4 and 5 are always positive. In some situations, 3 is considered positive.

Oral Boards (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions